Signal from the log
Superluminal Medicines
60 M$ · Series B · United States · Biotech
Biotech de Boston qui conçoit des petites molécules contre les récepteurs GPCR, en produisant ses propres structures par cryo-microscopie électronique et en les combinant à des modèles de conception moléculaire. Son premier candidat est un agoniste biaisé du récepteur MC4R, destiné aux obésités génétiques rares et à l'obésité hypothalamique, avec une phase 1 attendue d'ici fin 2026.
Article
Announced on , logged by the watch of 3 September 2026.
- Operation
- Funding round
- Announced amount
- 60 M$
- Stage
- Series B
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by BVF Partners , with Deep Track Capital , Perceptive Advisors
Provenance
Source edgar,endpoints,prnewswire
Logged on 3 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.